Is NAD one pool in the cell?

No. Mitochondria, nucleus and cytosol maintain distinct pools that do not freely exchange, because the inner mitochondrial membrane is impermeable to these molecules.

How do electrons cross if the cofactor cannot?

Through shuttle systems that transfer reducing equivalents onto a crossable metabolite, which is reoxidised on the other side.

Why does compartmentalisation complicate measurement?

A tissue homogenate averages across compartments never in equilibrium, so a total can be unchanged while individual pools move in opposite directions.

NAD+

Separate Pools in Separate Compartments

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Nicotinamide dinucleotides do not form one freely mixing pool. Mitochondria, nucleus and cytosol maintain distinct concentrations, and Zhu and colleagues showed in Science in 2021 that mitochondrial NADP(H) generation specifically is essential for proline biosynthesis.

Key facts

Compartments: Mitochondria, nucleus, cytosol
Pools: Distinct, not freely exchanging
Barrier: Inner mitochondrial membrane
2021 finding: Zhu, Science (PMID 33888598)
Specific requirement: Mitochondrial NADP(H) for proline synthesis
Implication: Total concentration is not the whole story

Why the pools stay separate

The inner mitochondrial membrane is not permeable to nicotinamide dinucleotides. They cannot simply diffuse in or out, which means the mitochondrial pool is maintained independently of the cytosolic one and the two can sit at different concentrations and different redox states simultaneously.

How electrons cross when the molecules cannot

Through shuttle systems. Reducing equivalents are transferred onto a metabolite that can cross the membrane, and the metabolite is reoxidised on the other side. The electrons move; the cofactor does not. That is an elegant solution and it means transfer is regulated rather than automatic.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

What the 2021 Science paper established

Zhu and colleagues showed that mitochondrial NADP(H) generation is essential for proline biosynthesis. The requirement is compartment-specific — cytosolic supply does not substitute. That is direct evidence the pools are functionally as well as physically separate, since if they mixed the distinction could not exist.

Why this complicates measurement

A tissue NAD+ measurement made from a homogenate averages across compartments that were never in equilibrium. A total concentration can be unchanged while one compartment falls and another rises, and the two situations are biologically quite different. Whole-tissue numbers describe a sum, not a state.

And why it complicates supplementation reasoning

Raising a measured total says nothing about which compartment received it. Since the consuming enzymes are distributed unevenly — sirtuins across several compartments, PARPs largely nuclear, CD38 extracellular — where an increase lands determines what it could affect. The question is not only how much but where.

What this does not claim

Anything about supplementation outcomes in any person. It describes cellular organisation established in the biochemical literature. Material supplied here is for laboratory research only, and no claim is made about metabolism, ageing or any condition.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is NAD one pool in the cell?: No. Mitochondria, nucleus and cytosol maintain distinct pools that do not freely exchange, because the inner mitochondrial membrane is impermeable to these molecules.
How do electrons cross if the cofactor cannot?: Through shuttle systems that transfer reducing equivalents onto a crossable metabolite, which is reoxidised on the other side.
Why does compartmentalisation complicate measurement?: A tissue homogenate averages across compartments never in equilibrium, so a total can be unchanged while individual pools move in opposite directions.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum